Evidence map›Paper›PMID 32655683›Full record

ArticleChinese medicine2020

Multiple circulating alkaloids and saponins from intravenous Kang-Ai injection inhibit human cytochrome P450 and UDP-glucuronosyltransferase isozymes: potential drug-drug interactions.

Zifei Qin, Mengmeng Jia, Jing Yang, Han Xing, Zhao Yin, Zhihong Yao, Xiaojian Zhang, Xinsheng Yao

Open access · goldAbstract read
In one paragraph

Article in Chinese medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Zifei QinDepartment of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052 China.ORCID 0000-0001-8989-1986
Mengmeng JiaDepartment of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052 China.
Jing YangDepartment of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052 China.
Han XingDepartment of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052 China.
Zhao YinDepartment of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052 China.
Zhihong YaoGuangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, Jinan University, Guangzhou, 510632 China.
Xiaojian ZhangDepartment of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052 China.
Xinsheng YaoGuangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, Jinan University, Guangzhou, 510632 China.
Zhengzhou University · CNJinan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundKang-Ai injection is widely used as an adjuvant therapy drug for many cancers, leukopenia, and chronic hepatitis B. Circulating alkaloids and saponins are believed to be responsible for therapeutic effects. However, their pharmacokinetics (PK) and excretion in vivo and the risk of drug-drug interactions (DDI) through inhibiting human cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT) enzymes remain unclear.

methodsPK and excretion of circulating compounds were investigated in rats using a validated ultra-high-performance liquid chromatography tandem mass spectrometry (UHPLC-MS) method. Further, the inhibitory effects of nine major compounds against eleven CYP and UGT isozymes were assayed using well-accepted specific substrate for each enzyme.

resultsAfter dosing, 9 alkaloids were found with

conclusionsWe summarized the PK behaviors, excretion characteristics and protein binding rates of circulating alkaloids, astragalosides and ginsenosides after intravenous Kang-Ai injection. Furthermore, weak inhibition or no inhibition towards these CYP and UGT activities could not trigger harmful DDI when Kang-Ai injection is co-administered with clinical drugs primarily cleared by these CYP or UGT isozymes.

Indexed as

Cytochrome P450Drug–drug interactionsExcretionKang-Ai injectionPharmacokineticsPlasma protein binding rateUDP-glucuronosyltransferase

Identifiers

PMID32655683
PMCPMC7339578
OpenAlexW3040149594

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.